XML 67 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaboration and Other Agreements - Celera Corporation, Narrative (Details) (USD $)
1 Months Ended 3 Months Ended
Apr. 30, 2006
Mar. 31, 2015
Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Milestone payment for HDAC Inhibitor two-thirds    
Milestone Payment For HDAC Inhibitor Percentage 66.66%pcyc_MilestonePaymentForHDACInhibitorPercentage    
Milestone Payment For Factor VIIa one-third    
Milestone Payment For Factor VIIa Percentage 33.33%pcyc_MilestonePaymentForFactorVIIaPercentage    
Celera Corporation Agreement [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Maximum milestone payments 97,000,000pcyc_MaximumMilestonePayments
/ us-gaap_TypeOfArrangementAxis
= pcyc_CeleraCorporationAgreementMember
   
Potential future milestone payments to be paid to Celera after regulatory approval 90.00%pcyc_PotentialFutureMilestonePaymentsToBePaidToCeleraAfterRegulatoryApprovalAsPercentage
/ us-gaap_TypeOfArrangementAxis
= pcyc_CeleraCorporationAgreementMember
   
Collaborative agreement, termination terms, days written notice to terminate agreement 60 days    
Collaborative agreement, termination terms, days of written notice that breaching party has to cure a breach in contract before termination 90 days    
Celera Corporation Agreement [Member] | IMBRUVICA [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Royalty Expense   $ 11,800,000us-gaap_RoyaltyExpense
/ us-gaap_ProductOrServiceAxis
= pcyc_IMBRUVICAMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CeleraCorporationAgreementMember
$ 3,900,000us-gaap_RoyaltyExpense
/ us-gaap_ProductOrServiceAxis
= pcyc_IMBRUVICAMember
/ us-gaap_TypeOfArrangementAxis
= pcyc_CeleraCorporationAgreementMember